RIGL - リジェル・ファ―マシュ―ティカルズ (Rigel Pharmaceuticals Inc.) リジェル・ファ―マシュ―ティカルズ

 RIGLのチャート


 RIGLの企業情報

symbol RIGL
会社名 Rigel Pharmaceuticals Inc (リジェル・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 リジェル・ファーマシューティカルズ(Rigel Pharmaceuticals Inc.)は臨床段階のバイオ技術会社である。同社は免疫および血液学的疾患、癌および希少疾患を有する患者の生活を改善する新規小分子薬物の発見、開発および提供に従事する。同社の研究は疾患メカニズムにシグナル伝達経路に焦点を当てる。同社の製品には、持続性の免疫血小板減少症(ITP)患者の治療のための経口脾臓チロシンキナーゼ(SYK)阻害剤が含まれる。現在の臨床プログラムは、自己免疫性溶血性貧血およびIgA腎症におけるフォスタマチニブの第2相試験、インターロイキンレセプター関連キナーゼ(IRAK)プログラムに関する第I相試験を含む。さらに、BerGenBio AS、第一三共、Aclaris Therapeuticsなどのパートナーと開発候補製品を提供する。   リジェル・ファ―マシュ―ティカルズは、米国の製薬企業。炎症性・自己免疫疾患やがん、ウイルス性および代謝性の疾患領域で小分子化合物の医薬品の創薬から開発までを行う。リウマチ性関節炎、血小板減少症、喘息などの製品開発に取り組む。本社はカリフォルニア州サウスサンフランシスコ。   Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with hematologic disorders, cancer and rare immune diseases. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA approved product is TAVALISSE® (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The product is also commercially available in Europe (TAVLESSE) and Canada (TAVALISSE) for the treatment of chronic immune thrombocytopenia in adult patients.
本社所在地 1180 Veterans Blvd. South San Francisco CA 94080 USA
代表者氏名 Raul R. Rodriguez ラウル・R・ロドリゲス
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 650-624-1100
設立年月日 35217
市場名 NASDAQ National Market System
ipoyear 2000年
従業員数
url www.rigel.com
nasdaq_url https://www.nasdaq.com/symbol/rigl
adr_tso
EBITDA EBITDA(百万ドル) -94.41800
終値(lastsale) 3.25
時価総額(marketcap) 540941186.5
時価総額 時価総額(百万ドル) 496.00150
売上高 売上高(百万ドル) 2.68700
企業価値(EV) 企業価値(EV)(百万ドル) 361.00950
当期純利益 当期純利益(百万ドル) -93.47300
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Rigel Pharmaceuticals Inc. revenues decreased 50% to $1.8M. Net loss increased 45% to $49.9M. Revenues reflect Contract revenues from collaborations decrease from $3.6M to $0K. Higher net loss reflects General and administrative - Balancing v increase from $13.9M to $28.8M (expense) Gain on disposal of assets decrease from $732K (income) to $0K.

 RIGLのテクニカル分析


 RIGLのニュース

   Why Are Chinese Stocks BABA, BILI, IQ Up Today?  2022/12/02 17:25:33 InvestorPlace
Source: Sean Pavone / Shutterstock Chinese stocks are climbing higher on Friday as investors continue to hope that the country will ease off of Covid-19 restrictions . China remains one of the few countries in the world still holding firm to lockdowns and restrictions due to the pandemic. However, that’s been weighing on its economy for some time and is causing problems. There’s been increasing talk lately that China will abandon its Zero Covid policy in favor of a full reopening. While that hasn’t happened yet, the country is moving forward with vaccination and booster shots ahead of a potential reopening. When Will China Reopen? Current forecasts have China reopening in the first half of 2023 . This isn’t an official outline from the Chinese government. Instead, it’s expectations from experts as they predict the country will slowly loosen restrictions in the coming months. And those predictions are doing wonders for Chinese stocks today. Several shares are on the rise as investors regain hope that lockdowns in the country will come to an end soon.
   BBWI Stock Climbs as Bath & Body Works Candle Day Sale Kicks Off  2022/12/02 17:08:33 InvestorPlace
Source: Moab Republic / Shutterstock.com Bath & Body Works (NYSE: BBWI ) stock is rising higher on Friday as the retail company starts its annual Candle Day sale . Members of Bath & Body Works’ loyalty program got an early start when the Candle Day sale started late on Thursday. However, it opened up to the public today and will last through Saturday. So long as supplies last. Bath & Body Works often sells out of candles during the event and this time around will likely be no different. That’s due to it offering three-wick candles for $9.95, which it calls pre-pandemic pricing. These types of candles haven’t been that cheap since 2020. Why This Matters for BBWI Stock Bath & Body Works looks to be drawing in a huge crowd for holiday shopping as customers load up on presents for family and friends. This latest sale builds on an already successful Black Friday and Cyber Monday for the retailer. If all goes well, BBWI investors will likely be celebrating when the company releases its holiday earnings report.
   Gold Down 1%; Samsara Shares Spike Higher  2022/12/02 17:06:59 Benzinga
U.S. stocks traded lower midway through trading, with the Dow Jones falling around 75 points on Friday. The Dow traded down 0.22% to 34,319.84 while the NASDAQ fell 0.71% to 11,401.44. The S&P 500 also fell, dropping, 0.47% to 4,057.57. Also check this: Ethereum Edges Lower But Remains Above This Key Level; Dogecoin Becomes Top Loser Leading and Lagging Sectors Energy shares rose by 0.1% on Friday. Leading the sector was strength from Borr Drilling Limited (NYSE: BORR ) and CONSOL Energy Inc. (NYSE: CEIX ). In trading on Friday, information technology shares fell by 1.4%. Top Headline The US economy unexpectedly added 263,000 jobs in November, following a revised 284,000 gain in October and also surpassing market estimates of 200,000. The unemployment rate came in unchanged at 3.7% in November, while average hourly earnings increased by 0.6% to $32.82 in November. Equities Trading UP Samsara Inc. (NYSE: IOT ) shares shot up 18% to $11.67 after the company reported better-than-expected Q3 results and issued FY23 guidance above estimates.
   Rigel upgraded at Citi on bullish outlook for new leukemia drug  2022/12/02 16:52:59 Seeking Alpha
Citi upgraded Rigel Pharmaceuticals (RIGL) to Buy from Neutral on Friday after the biotech announced the U.S
   Rigel Pharmaceuticals (RIGL) Stock Soars on FDA Approval News  2022/12/02 16:17:52 InvestorPlace
Source: Shutterstock Rigel Pharmaceuticals (NASDAQ: RIGL ) stock is heading higher on Friday after getting approval from the U.S. Food and Drug Administration (FDA) for its leukemia treatment. Specifically, the FDA has approved REZLIDHIA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 mutation. The drug works by reducing 2-hydroxyglutarate levels, which restores normal cellular differentiation of myeloid cells. Rigel Pharmaceuticals already has an exclusive worldwide agreement with Forma Therapeutics for the development, manufacturing, and commercialization of REZLIDHIA. This will have Rigel Pharmaceuticals handling the U.S. launch of the drug. It also intends to seek out partners for worldwide distribution. Raul Rodriguez, president and CEO of Rigel Pharmaceuticals, said the following about the approval. “We are delighted by the approval of REZLIDHIA based on the strength of data supporting the efficacy and safety of the product.
   These strategies will help Rigel Pharmaceuticals Inc. (RIGL) succeed  2022/09/16 13:16:00 US Post News
The share price of Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) rose to $1.32 per share on Thursday from $1.28. While Rigel Pharmaceuticals Inc. has overperformed by 3.13%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, RIGL fell by -65.62%, with highs and lows ranging from $3.95 to $0.64, […]
   Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) Stock Could Be An Option To Consider  2022/09/16 12:30:00 Stocks Register
Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) shares, rose in value on Thursday, 09/15/22, with the stock price up by 3.13% to the previous day’s close as strong demand from buyers drove the stock to $1.32. Actively observing the price movement in the last trading, the stock closed the session at $1.28, falling within a range of $1.26 … Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) Stock Could Be An Option To Consider Read More »
   Sizzling Ways To Make you Sure for investment: Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL -1.54%), Inuvo, Inc. (AMEX:INUV -0.68%)  2022/09/14 23:24:50 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Sizzling Ways To Make you Sure for investment: Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL -1.54%), Inuvo, Inc. (AMEX:INUV -0.68%) appeared first on Stocks Equity .
   Was anything negative for Rigel Pharmaceuticals Inc. (RIGL) stock last session?  2022/09/12 13:32:00 US Post News
A share of Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) closed at $1.43 per share on Friday, down from $1.44 day before. While Rigel Pharmaceuticals Inc. has underperformed by -0.69%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, RIGL fell by -64.25%, with highs and lows ranging from $4.07 […]
   Analysts Provide Insight On How High Rigel Pharmaceuticals Inc. (RIGL) Can Go  2022/09/02 13:30:00 Stocks Register
Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) concluded the trading at $1.54 on Thursday, September 01 with a rise of 8.45% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $1.42 and 5Y monthly beta was reading 1.66 with its price kept floating in the … Analysts Provide Insight On How High Rigel Pharmaceuticals Inc. (RIGL) Can Go Read More »
   Thrombopoietin Receptor Agonist Market Significantly Stepping towards the Success Till 2027| Amgen, Novartis, Rigel Pharmaceuticals  2021/08/27 12:08:28 OpenPR
Prior to the widespread availability of thrombopoietin receptor agonists (TPO-RA), splenectomy and rituximab were the most prevalent second-line therapies for patients with immunological thrombocytopenia (ITP). Both approaches have the potential to cure the disease. Long-term answers, on the other hand,
   SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rigel Pharmaceuticals, Inc. - RIGL  2021/08/16 20:30:00 PR Newswire
NEW YORK, Aug. 16, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rigel Pharmaceuticals, Inc. ("Rigel" or the "Company") (NASDAQ: RIGL). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The
   Rigel Stock Falls After Update From COVID-19 Program  2021/08/13 12:21:15 Business Insider Markets
The FDA has informed Rigel Pharmaceuticals Inc (NASDAQ: RIGL ) that data submitted in May from fostamatinib Phase 2 trial
   Rigel : FDA Didn''t Issue EUA For Fostamatinib For Treatment Of COVID-19 In Hospitalized Adults  2021/08/13 11:54:15 Business Insider Markets
(RTTNews) - Rigel Pharmaceuticals Inc. (RIGL) said Friday that the U.S. Food and Drug Administration did not issue emergency use authorization for fostamatinib for the treatment of COVID-19 in hospitalized adults, due to insufficient clinical data. In Friday pre-market trade, RIGL was trading at $3.60, down $0.53 or 12.83%. "The FDA has
   Astounding Stock: Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), ShiftPixy, Inc. (NASDAQ:PIXY)  2021/08/09 22:54:15 Stock Equity
Rigel Pharmaceuticals, Inc. (RIGL) with the stream of 1.71% also noticed, India ShiftPixy, Inc. (PIXY) encountered a rapid change of -1.37% in the last hour of Mondays trading session. Rigel The post Astounding Stock: Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), ShiftPixy, Inc. (NASDAQ:PIXY) appeared first on Stocks Equity .

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 リジェル・ファ―マシュ―ティカルズ RIGL Rigel Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)